Published on 14 Nov 2023 on Zacks · via Yahoo Finance
Atara Biotherapeutics (ATRA) Slumps 57% in a Month: Here's Why
Atara Biotherapeutics ATRA is a biotech company focused on developing off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune conditions.
The company utilizes its proprietary technology platform to develop novel therapies that target Epstein-Barr virus (EBV)-driven diseases.
The most advanced T-cell immunotherapy program in Atara’s pipeline is tabelecleucel (tab-cel). It is currently being evaluated in a phase III study in the United States for EBV-associated post-transplant lymphoproliferative disease (EBV+ PTLD). The therapy received approval in Europe last year for EBV+ PTLD indication. It is being marketed with the trade name Ebvallo by Pierre Fabre Medicament under an exclusive commercialization and license agreement.